PROMACTA has been proven to help pediatric patients with persistent or chronic immune thrombocytopenia (ITP) reach target levels and maintain them for a long time

PROMACTA has been proven to help pediatric patients with persistent or chronic immune thrombocytopenia (ITP) reach target levels and maintain them for a long time

Primary End Point

PETIT (Study 1): The primary end point was the proportion of patients achieving platelet counts ≥50,000/mcL at least once between Days 8 and 43 (Weeks 1 to 6) of the randomized period.

PETIT 2 (Study 2): The primary end point was the proportion of patients achieving platelet counts ≥50,000/mcL at least 6 of the 8 weeks between Weeks 5 to 12 of the randomized period.

Study Design

PETIT (Study 1): Open-label, double blind, randomized, placebo-controlled study to investigate the efficacy, safety, tolerability, and pharmacokinetics of eltrombopag in previously treated pediatric patients (n=67) with persistent or chronic ITP.

PETIT 2 (Study 2): Open-label, double-blind, randomized, placebo-controlled study to investigate the efficacy, safety, and tolerability of eltrombopag in previously treated pediatric patients (n=92) with chronic ITP.

See what others living with ITP prefer

See what others living with ITP prefer

Patients with ITP prefer once-daily oral dosing

The ITP World Impact Survey (I-WISh) was a global survey conducted in 13 countries with 1507 patients and 472 physicians. In the US alone, there were more than 500 patients. The survey asked about patient preference for administration. Here’s what it found:

 

• Most patients, 87%, said they prefer treatment that could be taken by mouth once a day (over an injectable therapy or a twice-daily oral regimen)